Loading...

Livzon Pharmaceutical Group Inc.

1513.HKHKSE
HealthcareDrug Manufacturers - Specialty & Generic
HK$29.15
HK$0.50(1.75%)

Livzon Pharmaceutical Group Inc. 1513.HK Peers

See (1513.HK) competitors and their performances in Stock Market.

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
1513.HKHK$29.15+1.75%33.3B11.66HK$2.50+5.55%
3692.HKHK$26.50+1.92%157.6B33.13HK$0.80N/A
2196.HKHK$16.00+3.09%65.8B13.33HK$1.20+2.05%
0874.HKHK$17.72+2.19%46B9.79HK$1.81+7.80%
3320.HKHK$5.17+2.17%32.5B8.91HK$0.58+6.12%
0512.HKHK$9.14+4.70%32B13.06HK$0.70+5.69%
3933.HKHK$15.34+7.57%27.9B9.65HK$1.59+4.01%
0867.HKHK$10.72+2.49%25.9B14.68HK$0.73+2.96%
0013.HKHK$23.20+7.41%20.2B74.84HK$0.31N/A
9989.HKHK$5.21+6.33%18.4B10.85HK$0.48+4.78%
Showing 1 to 10 of 42 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

1513.HK vs 3692.HK Comparison

1513.HK plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 1513.HK stands at 33.3B. In comparison, 3692.HK has a market cap of 157.6B. Regarding current trading prices, 1513.HK is priced at HK$29.15, while 3692.HK trades at HK$26.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

1513.HK currently has a P/E ratio of 11.66, whereas 3692.HK's P/E ratio is 33.13. In terms of profitability, 1513.HK's ROE is +0.15%, compared to 3692.HK's ROE of +0.15%. Regarding short-term risk, 1513.HK is less volatile compared to 3692.HK. This indicates potentially lower risk in terms of short-term price fluctuations for 1513.HK.

Stock Price Comparison

Loading...

Frequently Asked Questions